Document is current
Any future updates will be listed below
-
Authors
Chiu, Joanne
Su, Fei
Joshi, Mukta
Masuda, Norikazu
Ishikawa, Takashi
Aruga, Tomoyuki
Zarate, Juan Pablo
Babbar, Naveen
Balbin, O. Alejandro
Yap, Yoon-Sim http://orcid.org/0000-0002-0347-5066
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
- License Information
-
More Information
Article History
Received: 7 February 2023
Accepted: 1 August 2023
First Online: 15 August 2023
Declarations
:
: Written informed consent was obtained from all patients. The trial was designed, implemented, and reported in accordance with Good Clinical Practice, all applicable regulatory requirements, and the guiding principles of the Declaration of Helsinki. The study protocol and amendments were reviewed and approved by the local independent ethics committees.
: Not applicable.
: Joanne Chiu has nothing to disclose. Fei (Faye) Su reports employment and stock ownership from Novartis. Mukta Joshi reports employment from Novartis. Norikazu Masuda reports grants for research funding and personal fees for honoraria from Chugai, AstraZeneca, Eli Lilly, Eisai, and Pfizer; grants for research funding from Kyowa-Kirin, MSD, Novartis, Sanofi, Nihon-Kayaku, Daiichi-Sankyo. Takashi Ishikawa has nothing to disclose. Tomoyuki Aruga reports personal fees from AstraZeneca, Pfizer, Chugai-Pharm, Eli Lilly. Juan Pablo Zarate reports employment and stock ownership from Novartis. Naveen Babbar has nothing to disclose. Alejandro Balbin has nothing to disclose. Yoon-Sim Yap reports personal fees and travel support from Lilly/DKSH, AstraZeneca, Roche; personal fees from Novartis, Pfizer, Eisai, MSD, Inivata, Specialised Therapeutics.
